Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up
Key facts
- Who runs it
- Artcline GmbH
- Where
- Germany2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 142 people, planned
- Started
- 1 Jan 2024
- Expected to end
- 28 Feb 2030
- Type of study
- Observational, 2 groups
- Record updated
- 2 August 2024
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent
- Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial
Who cannot take part
- none
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial is currently available in Germany.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment.
Read full original descriptionShow less
In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.
The 2 groups in the trial
- Control group
Subjects in this group where randomized in the control group in the ReActiF-ICE study previously
- Therapy Group
Subjects in this group where randomized in the therapy group in the ReActiF-ICE study previously
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06143137, who can take part
- Record updated
- 2 August 2024